Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro
Ewelina Motylewska1, Hanna Lawnicka, Magdalena Kowalewicz-Kulbat
1hstep@csk.umed.lodzp.
Introduction:
Pheochromocytomas are benign or malignant neuroendocrine tumours. The unsatisfactory efficacy of the traditional therapeutic methods for patients with metastatic disease results in a continuing search for more effective and targeted agents. Due to the increased vascularisation of these tumours, inhibitors of angiogenesis could be potentially a new group of drugs in pheochromocytoma/paraganglioma therapy.
Material And Methods:
The aim of this study was to evaluate the influence of angiomodulators: VEGF (vascular endothelial growth factor) and five endogenous and exogenous antiangiogenic compounds (endostatin; IFN-alpha [interferon alpha]; rapamycin - mTOR [mammalian target of rapamycin] inhibitor; JV1-36 and SU5416 (semaxinib]) on the growth of rat pheochromocytoma PC12 cell line.
Results:
IFN-alpha (10(5) U/mL) strongly inhibited PC12 growth in a 72 h culture, increasing apoptosis and arresting the cell cycle. Rapamycin in a wide range of concentrations (10(-5) to 10(-8) M) induced a slight inhibitory effect on PC12 viability and decreased cell proliferation at the concentration of 10(-5) M. VEGF, endostatin and JV1-36 did not influence the growth of PC12.
Conclusions:
The study has shown for the first time that IFN-a inhibited the growth of pheochromocytoma PC12 line and confirmed the inhibitory action of rapamycin on these cells. The results suggest that IFN-alpha and mTOR inhibitors could be potentially effective in the therapy of malignant pheochromocytoma, and encourage further study in this field.
Insights
Interferon-alpha (IFN-alpha) and rapamycin show promise in treating pheochromocytoma. These agents inhibited tumor cell growth, suggesting potential as targeted therapies for malignant neuroendocrine tumors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Pheochromocytomas are neuroendocrine tumors with limited treatment options for metastatic disease.
- Targeted therapies, particularly anti-angiogenic agents, are being explored due to tumor vascularization.
Purpose of the Study:
- To investigate the anti-angiogenic potential of various compounds on rat pheochromocytoma PC12 cells.
- To evaluate the efficacy of vascular endothelial growth factor (VEGF) inhibitors and other modulators.
Main Methods:
- PC12 cell line was treated with VEGF, endostatin, interferon-alpha (IFN-alpha), rapamycin (mTOR inhibitor), JV1-36, and SU5416.
- Cell growth, apoptosis, and cell cycle arrest were assessed over 72 hours.
Main Results:
- IFN-alpha significantly inhibited PC12 cell growth, induced apoptosis, and arrested the cell cycle.
- Rapamycin demonstrated a slight inhibitory effect on cell viability and proliferation.
- VEGF, endostatin, and JV1-36 did not affect PC12 cell growth.
Conclusions:
- IFN-alpha is a potent inhibitor of pheochromocytoma PC12 cell growth.
- Rapamycin (mTOR inhibitor) also exhibits inhibitory effects on these tumor cells.
- IFN-alpha and mTOR inhibitors represent potential therapeutic strategies for malignant pheochromocytoma.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22PI3K/mTOR/AKT Signaling Pathway
01:30Inhibitors of Viral Protein Synthesis